The Rockefeller University

Sloan-kettering Institute for Cancer Research

University of California

Other

Massachusetts Institute of Technology

Bristol-myers Squibb Compnay

Jeffrey V Ravetch

Aaron Paul Yamniuk

Brigitte Devaux

K Dane Wittrup

Toshihiko Kobayashi

Andrew Pincetic

Taia T Wang

Jad Mamaary

Rony Dahan

Roger V Lebo

Hidehiro Fukuyama

Robert M Anthony

Yoshikatsu Kaneko

Falk Nimmerjahn

Brenda L Stevens

Bryan C Barnhart

Bice Perussia

Shannon Lee Okada

Rene Georg Ott

Ping Wang

Mikael Karlsson

Sam Danishefsky

Stephen Lael Sazinsky

Nimmerjahn Falk

Laura Pologe

Tomohiro Kurosaki

Raphael Clynes

Diana Sylvestre

Toshiyuki Takai

Rene G Ott

Fubin Li

Kaneko Yoshikatus

Fredrik Wermeling

Robert Anthony

This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.

Anti-inflammatory polypeptides

The present invention relates to immunogenic immune complexes, related compositions, and related methods.

Immune complex

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Antibodies to CD40 with enhanced agonist activity

The present invention relates to anti-tumor agents that target certain tumor-associated macrophages. Also disclosed are methods of using such agents in treatment of cancer.

Anti-tumor agents and methods of use

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (IC) or immune complexes (ICs), which take advantages of Type II Fc receptor (FcR) interactions and signaling to elicit broader and more potent protective immune responses. In one aspect, the invention provides an immune complex comprising an antigenic agent and an isolated protein. The protein comprises an IgG Fc region and is capable of binding to a Type II Fc receptor. Preferably, the protein is an antibody or an Fc region-containing fragment thereof.

The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.

Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Growing community of inventors

New York, NY, United States of America

Jeffrey V Ravetch